CURAS fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Curasight A/S is a clinical development company. It engages in the business of exploiting a novel theragnostic platform with positron emissions tomography imaging and radionuclide therapy targeting the urokinase-type plasminogen activator receptor. The company was founded by Morten Persson, Andreas Kjær, Carsten Haagen Nielsen, and Jacob Madsen in 2013 and is headquartered in Copenhagen, Denmark.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
CURAS has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company